Universal platform for CAR therapy targeting novel antigenic signatures of cancer

摘要

A nucleic acid molecule comprising a nucleotide sequence encoding an inhibitory chimeric antigen receptor (iCAR) capable of preventing or attenuating unwanted activation of effector immune cells, wherein iCAR is due to loss of heterozygosity (LOH) An extracellular domain that specifically binds to a single allelic variant of a polymorphic cell surface epitope that is not present in mammalian tumor cells but is present in at least all cells of the relevant mammalian normal tissue, and an effector immune cell Nucleic acid molecules comprising an intracellular domain comprising at least one signaling element to inhibit are provided. Further provided are vectors and transduced effector immune cells comprising the nucleic acid molecules, and methods for the treatment of cancer comprising administering the transduced effector immune cells.